Navigation Links
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
Date:6/16/2013

evelopment and Janssen Biotech are part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new informat
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Mass., May 6, 2015 NxStage Medical, Inc. (Nasdaq: ... products, today reported first quarter financial results that exceed ... Revenue for the first quarter of 2015 increased ... $72.2 million for the first quarter of 2014. The ... $77.5 million to $78.5 million.  The increase was driven ...
(Date:5/6/2015)... 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... that it will host a conference call and webcast ... the period ended March 31, 2015 and to provide ... clinical program for aramchol. Conference Call ...
(Date:5/6/2015)... 6, 2015   Sigma-Aldrich Corporation (NASDAQ: SIAL ... today announced a $50,000 product donation to the ... replicate key findings from recent high-impact papers in the ... between the online research marketplace Science Exchange , ... the open-access journal eLife. The goal of ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3
... the American,Society of Hematology (ASH) and the American ... joint guideline on the use of,erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat,chemotherapy-related ... to inform clinicians with the most,up-to-date evidence from ...
... and efficacy of TAXUS drug- ... stent compared to bare-metal stent, NATICK, Mass., and WASHINGTON, ... announced five-year and final,follow- up data from its TAXUS IV ... -- in patients who received a TAXUS(R),Express(TM) Paclitaxel-Eluting Coronary Stent ...
Cached Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 2Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 3Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 4
(Date:5/6/2015)... Anitha Nallari, MD has joined Shakir ... in Columbus, OH. Dr. Nallari will see patients with ... breast cancer, lung cancer, GI and gallbladder cancer, head and ... hematology. , Dr. Anitha Nallari is Board Certified ... Board of Internal Medicine. She completed her medical education in ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... The 2015 STEMtech conference exhibition hall ... booth selection . Don’t miss this opportunity to ... and university decision-makers from around the country. , This ... the Arizona Grand in Phoenix. This beautiful all-suite hotel ... doorstep of the South Mountain Preserve. The Phoenix area ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
(Date:5/6/2015)... New york, NY (PRWEB) May 06, 2015 ... on strategy, design, creative and technology, announced today that ... an expert advisor by Shocase, a marketing professional network ... the marketing sector. , Widely regarded as a specialist ... of the most high-profile branding programs over the last ...
Breaking Medicine News(10 mins):Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4Health News:Shocase Selects MBLM’s Claude Salzberger as Company Advisor 2
... survival of cells that are exposed to stress. Researchers at ... operation some time ago but now Hsp90 has surprised ... results are published in the current online issue of the ... cancer medication. Proteins are the motors of the cell: ...
... Playing "media detective" allows children to understand the intentions of ... resist messages that encourage alcohol or tobacco use. ... shows that teaching children as early as third grade to ... use. The study, based on the research of Erica Weintraub ...
... Steven Reinberg HealthDay Reporter , MONDAY, Aug. 23 ... potentially tainted by salmonella, the head of the U.S. Food ... additional sort of sub-recalls over the next couple of days, ... distribution of these eggs that are contaminated," agency director Margaret ...
... at math in school, so that,s what she pursued as a ... Houston, Texas, and met some cardiologists at a party, she started ... them. "I realized we could provide them with a fluid ... about, for example, which stent grafts they use in their procedures," ...
... flooding of New Orleans caused the evacuation of 1.5 ... remained displaced, many residing in highly transitional shelters, including ... mark, substantial consequences from this prolonged displacement have resulted ... the region, according to a new study by the ...
... Although the medical community has already accepted that colorectal ... researchers have found that computed tomography colonography (CTC or ... the yield of identifying significant early extracolonic (outside the ... study in the September issue of the American Journal ...
Cached Medicine News:Health News:Munich researchers demonstrate rocking movement in the anti-stress protein Hsp90 2Health News:'Media detective' tool empowers children to skirt alcohol and tobacco marketing messages 2Health News:FDA Chief Says More Egg Recalls Possible 2Health News:FDA Chief Says More Egg Recalls Possible 3Health News:FDA Chief Says More Egg Recalls Possible 4Health News:Math from the heart: Simulating stent design and coating 2Health News:Math from the heart: Simulating stent design and coating 3Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 2Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 3Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 4
... The Uniflex Humeral Nail System has been ... in which noninvasive treatments have historically failed ... a unique blend of strength and flexibility. ... strength of titanium alloy is twice that ...
... Building on a strong heritage, the ... a new standard in ophthalmic ultrasound instrumentation. ... options, OcuScan RxP makes it simple to ... reproducible. Designed to enhance patient care by ...
... The AIM Titanium Tibial ... address the mechanical failures of ... indications for tibial interlocking nails. ... full range of diameters and ...
Arthroscopic instrument system for instability and SLAP fixation....
Medicine Products: